Hypertrophic pachymeningitis is an uncommon inflammatory process with thickening of the dura mater and may be idiopathic or secondary to various conditions such as vasculitis, Sjögren syndrome, rheumatoid arthritis, sarcoidosis, and infections. A 67-year-old man who presented with bilateral hearing loss, vision loss in the left eye, right-sided facial paralysis, and right-side headache underwent 18F-FDG PET/CT for further evaluation. Herein, we have presented a patient who showed diffuse increased radiotracer uptake in the cranial nerves and intracranial dura mater on 18F-FDG PET/CT and was diagnosed as idiopathic hypertrophic pachymeningitis based on laboratory and MRI findings.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/RLU.0000000000005727 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Meta-analysis of 68Ga-FAPI PET in Assessment of Ovarian Cancer.
Acad Radiol
March 2025
Department of Nuclear Medicine, Beijing Luhe Hospital, Capital Medical University, Xinhua Road 82, Tong Zhou District, 101199 Beijing, China.
Rationale And Objectives: The objective of this research is to carry out a systematic review and meta-analysis to detect the diagnostic efficacy of 68Ga-FAPI Positron Emission Tomography (PET) Computed Tomography/Magnetic Resonance (CT/MR) in total of the lesions as well as different aspects of metastasis in individuals with ovarian cancers (OC).
Materials And Methods: The PubMed, Embase, Cochrane library, and Web of Science databases were thoroughly searched until the cut-off date of July 23, 2024. The assessment of 68Ga-FAPI PET CT/MR of OC was presented by the included studies.
Novel Clinical PET Tracers in the Pipeline for Melanoma.
Curr Oncol Rep
March 2025
Department of Nuclear Medicine, Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, The Netherlands.
Purpose: The aim of this review is to provide an overview of novel clinical PET tracers in the pipeline for melanoma. Secondarily, to provide a head-to-head comparison with the current clinical standard used in clinical practice, [F]FDG, if available.
Recent Findings: [F]FDG PET/CT has become important in the clinical setting for melanoma as it serves many purposes, but lacks other important qualities due its nonspecific nature.
Highlights from the breakout session: diagnosis and classification of vasculitis.
Rheumatology (Oxford)
March 2025
Rheumatology Department, Health New Zealand, Auckland, New Zealand.
The session on 'Diagnosis and Classification of Vasculitis' featured six oral presentations covering various aspects of vasculitis diagnosis and classification. The application of the Ankara criteria for IgA vasculitis in adults was evaluated, finding that while the criteria showed good sensitivity, their specificity was insufficient, suggesting the need for refinement. A clustering approach to classifying ANCA-associated vasculitis (AAV) identified five distinct clusters, which improved prediction of disease outcomes.
View Article and Find Full Text PDFThe value of whole-body MRI instead of only brain MRI in addition to 18 F-FDG PET/CT in the staging of advanced non-small-cell lung cancer.
Cancer Imaging
March 2025
Radiology, Department of Surgical Sciences, Uppsala University, Uppsala University Hospital, entry 70, 1st floor, Uppsala, 751 85, Sweden.
Background: Non-small cell lung cancer (NSCLC) is a common neoplasm with poor prognosis in advanced stages. The clinical work-up in patients with locally advanced NSCLC mostly includes F-fluorodeoxyglucose positron emission tomography computed tomography (F-FDG PET/CT) because of its high sensitivity for malignant lesion detection; however, specificity is lower. Diverging results exist whether whole-body MRI (WB-MRI) improves the staging accuracy in advanced lung cancer.
View Article and Find Full Text PDFFAPI radiopharmaceuticals in nuclear oncology and theranostics of solid tumours: are we nearer to surrounding the hallmarks of cancer?
Ann Nucl Med
March 2025
Department of Diagnostic Imaging (Radiology) and Nuclear Medicine, University Hospital San Pedro and Centre for Biomedical Research of La Rioja (CIBIR), Logroño, La Rioja, Spain.
[F]FDG PET/CT is the most widely used PET radiopharmaceutical in oncology, but it is not exempt of diagnostic limitations. FAPI have emerged as a great tool in the management of several different solid tumours in which [F]FDG is not able to provide enough information. The aim of this work was to evaluate the available evidence on diagnostic and therapeutic applications of PET/CT with FAPI radiopharmaceuticals.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!